128 related articles for article (PubMed ID: 8730248)
1. Twenty-four-hour intragastric acidity following early evening or bedtime administration of roxatidine in duodenal ulcer patients.
Lazzaroni M; Sangaletti O; Bargiggia S; Bensi G; Canali A; Bianchi Porro G
Aliment Pharmacol Ther; 1996 Apr; 10(2):187-91. PubMed ID: 8730248
[TBL] [Abstract][Full Text] [Related]
2. Effects of roxatidine acetate on 24-hour gastric acidity. Early evening versus bedtime administration in healthy subjects.
Hemery P; Congard P; Galmiche JP; Bonfils S
Drugs; 1988; 35 Suppl 3():76-81. PubMed ID: 2905253
[TBL] [Abstract][Full Text] [Related]
3. Double-blind, randomized trial of roxatidine 150 mg in the early evening versus bedtime administration in the short-term treatment of duodenal ulcer.
Lazzaroni M; Canali A; Bianchi Porro G
Aliment Pharmacol Ther; 1995 Aug; 9(4):425-31. PubMed ID: 8527619
[TBL] [Abstract][Full Text] [Related]
4. The effects of roxatidine acetate (HOE-760) on 24-hour intragastric acidity in healthy volunteers: comparison with ranitidine and placebo.
Merki HS; Witzel L; Kaufmann D; Kempf M; Müssig V; Neumann J; Scheurle E; Röhmel J; Walt RP
Aliment Pharmacol Ther; 1988 Feb; 2(1):73-81. PubMed ID: 2908751
[TBL] [Abstract][Full Text] [Related]
5. Absence of tolerance in duodenal ulcer patients treated for 28 days with a bedtime dose of roxatidine or ranitidine.
Savarino V; Mela GS; Zentilin P; Cutela P; Vigneri S; Termini R; Di Mario F; Ferrana M; Malesci A; Belicchi M; Celle G
Fundam Clin Pharmacol; 1996; 10(3):304-8. PubMed ID: 8836705
[TBL] [Abstract][Full Text] [Related]
6. [Early evening and late evening administration of roxatidine acetate in therapy of duodenal ulcer].
Bosseckert H; Ernst R; Kriech W; Schunter C
Med Klin (Munich); 1993 Nov; 88(11):637-41. PubMed ID: 7905185
[TBL] [Abstract][Full Text] [Related]
7. Assessment of intragastric acidity in man: modern aspects, reproducibility of intragastric pH-monitoring, and pharmacodynamic results obtained with H2-receptor antagonists.
Merki HS; Witzel L; Kaufmann D; Kempf M; Muessig V; Neumann J; Scheurle E; Roehmel J; Walt RP
Scand J Gastroenterol Suppl; 1988; 146():142-52. PubMed ID: 2906458
[TBL] [Abstract][Full Text] [Related]
8. Sufotidine 600 mg bd virtually eliminates 24 hour intragastric acidity in duodenal ulcer subjects.
Smith JT; Pounder RE
Gut; 1990 Mar; 31(3):291-3. PubMed ID: 1969833
[TBL] [Abstract][Full Text] [Related]
9. A multicenter, double-blind, randomized, placebo-controlled comparison of nocturnal roxatidine in the treatment of active duodenal ulcer disease. Multicenter Roxatidine Cooperative Study Group.
Gilinsky NH; Bright-Asare P; Cobert BL; Fitch DD; Lanza FL; Kerr RM; Savitsky JP
Am J Gastroenterol; 1992 Jul; 87(7):847-53. PubMed ID: 1352083
[TBL] [Abstract][Full Text] [Related]
10. The effects of roxatidine acetate on 24-hour intragastric acidity. Investigations in healthy volunteers and comparison with ranitidine and placebo.
Merki HS; Witzel L; Kaufmann D; Kempf M; Neumann J; Scheurle E; Röhmel J; Walt RP
Drugs; 1988; 35 Suppl 3():69-75. PubMed ID: 2905252
[TBL] [Abstract][Full Text] [Related]
11. Roxatidine versus ranitidine in the treatment of duodenal ulcer: a randomized, double blind, controlled, multicenter study in Thailand.
Kachintorn U; Chinapak O; Vongphanich V; Kositchaiwat C; Lekhayananda S; Khow-ean U; Suttinont C; Saowaros V; Kludchareon N; Leethochawalit M
J Med Assoc Thai; 1995 Dec; 78(12):641-7. PubMed ID: 8868007
[TBL] [Abstract][Full Text] [Related]
12. Roxatidine versus ranitidine in the treatment of patients with duodenal ulcer: a randomized, double-masked, multicenter study.
Zuberi SJ; Khan AQ; Irshad-ul-Haque I; Hussain A; Hasnain SS; Shah S; Sadick A; Yusuf MZ; Reuter M
Clin Ther; 1996; 18(6):1207-12. PubMed ID: 9001837
[TBL] [Abstract][Full Text] [Related]
13. Low bedtime doses of H2-receptor antagonists for acute treatment of duodenal ulcer.
Savarino V; Mela GS; Zentilin P; Bonifacino G; Moretti M; Valle F; Celle G
Dig Dis Sci; 1989 Jul; 34(7):1043-6. PubMed ID: 2568246
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics and pharmacodynamics of roxatidine in patients with renal insufficiency.
Gladziwa U; Wagner S; Sieberth HG; Klotz U
Br J Clin Pharmacol; 1995 Feb; 39(2):161-7. PubMed ID: 7742154
[TBL] [Abstract][Full Text] [Related]
15. A comparison of roxatidine acetate 150 mg once daily and 75 mg twice daily in duodenal ulcer healing.
Hentschel E; Schütze K
Drugs; 1988; 35 Suppl 3():96-101. PubMed ID: 2905256
[TBL] [Abstract][Full Text] [Related]
16. Roxatidine in duodenal ulcer.
Habibullah CM; Habeeb MA; Singh SP
J Postgrad Med; 1995; 41(3):64-5. PubMed ID: 10707717
[TBL] [Abstract][Full Text] [Related]
17. Is the time of dosing of a potent long-acting H2-receptor antagonist critical? Twenty-four-hour pH measurements with SKF-94482.
Wilder-Smith CH; Merki HS
Scand J Gastroenterol; 1991 May; 26(5):501-7. PubMed ID: 1678550
[TBL] [Abstract][Full Text] [Related]
18. Single bedtime dose of famotidine: assessment of its antisecretory action by 24-hour intragastric pH monitoring.
Savarino V; Picciotto A; Magnolia MR; Scalabrini P; Mela GS; Celle G
J Clin Pharmacol; 1987 Oct; 27(10):790-3. PubMed ID: 2892864
[TBL] [Abstract][Full Text] [Related]
19. Clinical characteristics of roxatidine acetate: a review.
Dammann HG; de Looze SM; Bender W; Labs R
Scand J Gastroenterol Suppl; 1988; 146():121-34. PubMed ID: 2906456
[TBL] [Abstract][Full Text] [Related]
20. Roxatidine versus ranitidine in the treatment of duodenal ulcers: a randomized double-blind controlled multicentre study in Singapore.
Fock KM; Kang JY; Ng HS; Ng TM; Gwee KA; Lim CC
J Gastroenterol Hepatol; 1995; 10(4):379-82. PubMed ID: 8527701
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
